+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06770582

Comparing Pembrolizumab Plus Radiation to Chemotherapy Plus Radiation for High-Grade T1 Bladder Cancer in a Phase II Trial

Led by National Cancer Institute (NCI) · Updated on 2026-10-19

160

Participants Needed

147

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are comparing two treatment methods for patients with high-grade T1 non-muscle invasive bladder cancer. This phase II trial evaluates pembrolizumab combined with radiation therapy against the usual chemotherapy regimens paired with radiation. Pembrolizumab, an immunotherapy drug, may help the immune system attack cancer cells, while chemotherapy drugs and radiation therapy work to kill or stop the growth of tumor cells. The goal is to see which combination better controls the cancer while preserving the bladder. Participants are randomly assigned to one of two groups. One group receives chemotherapy drugs chosen by their physiciancisplatin weekly for 4 weeks, gemcitabine on multiple days over several weeks, or mitomycin with continuous 5-fluorouracil infusionsalong with radiation therapy delivered in 20, 32, or 36 sessions over 4 to 7 weeks. The other group receives pembrolizumab infusions every 6 weeks for up to 9 cycles, also combined with the same radiation therapy schedule. Treatments continue as long as the disease does not progress and side effects remain acceptable. Throughout the study, participants undergo CT and MRI scans and provide blood samples, with optional urine samples. After completing treatment, participants are followed regularly for up to 10 years, with visits every 3 months for 2 years, every 6 months for 3 years, then annually for 5 years. Researchers monitor bladder intact event-free survival, quality of life, response by cystoscopy, disease-free and overall survival, local and metastatic cancer control, and side effects. Quality of life questionnaires and fatigue assessments are also completed to understand the broader impact of treatments.

CONDITIONS

Brief Title

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here